Importantly, pre-treatment with a CX3CR1 antagonist can help rescue this migration, further indicating the central role that fractalkine plays in NK cell phenotype, function and migration in obesity-associated cancer. This evidence concerns the gene CX3CR1 and obesity due to melanocortin 4 receptor deficiency.